Awaiting development: Guidance and quality standards

Showing 111 to 120 of 285

Guidance and quality standards awaiting development
Title	Type
Galcanezumab for migraine [TSID10663]	Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]	Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ianalumab for treating active Sjogren's syndrome [TSID12247]	Technology appraisal guidance